U.S. Diabetes Pipeline Outlook


Regular Price: USD 4,950.00

Special Price USD 3,465.00

30% OFF

* Required Fields

Regular Price: USD 4,950.00

Special Price USD 3,465.00


Be the first to review this product

This research service covers the pharmaceutical industry development pipeline for diabetes mellitus in the United States, with 2005 as the base year. Included are both the products projected to enter the market by the end of the forecast coverage period in 2012, as well as products entering the market in 2005 that correspond to the in-depth discussion drug classes. The focus of this piece is on pipeline technology developments and has greater focus on: GLP-1 Agonists, DPP-IV Inhibitors; PPAR Modulators; and Pulmonary Insulin. Also discussed are pipeline developments in other areas of oral antidiabetic drugs, injectables, and insulins other than pulmonary. Product Analysis charts are included for those products

Table of Contents

U.S. Diabetes Pipeline Outlook, Executive SummaryExecutive SummaryIntroductionU.S. Diabetes Pipeline Outlook, Market IntroductionResearch Scope and MethodologyScope and SegmentationResearch MethodologyDiabetes OverviewIntroductionTypes of DiabetesPrevalenceIncidenceCurrent TreatmentPipeline Competitive AnalysisIntroductionKey Pipeline CompaniesAreas of OpportunityU.S. Diabetes Pipeline Outlook, GLP-1 AgonistsIntroductionGLP-1 Agonist DynamicsGLP-1 Agonists Pipeline AnalysisByetta - Amylin & Eli LillyGLP-1 Agonist PipelineU.S. Diabetes Pipeline Outlook, Pulmonary InsulinIntroductionPulmonary Insulin DynamicsPulmonary Insulin AnalysisExubera - Pfizer & NektarPulmonary Insulin PipelineU.S. Diabetes Pipeline Outlook, DPP-IV InhibitorsIntroductionDPP-IV DynamicsDPP-IV Pipeline AnalysisPipeline AnalysisU.S. Diabetes Pipeline Outlook, PPAR ModulatorsIntroductionPPAR DynamicsPPAR Pipeline AnalysisPPAR PipelineDiscontinued PPAR ModulatorsU.S. Diabetes Pipeline Outlook, Other Pipeline EffortsIntroductionOther Development EffortsPipeline OverviewsOther Insulin PipelineOther OAD PipelineOther IAD PipelineU.S. Diabetes Pipeline Outlook, AppendixDecision Support DatabasesIncidence of DiabetesPrevalence of DiabetesDiabetes Prevalence as a Percentage of Total PopulationDiabetes Foot Ulcer Prevalence as a Percentage of Total PopulationTotal Population

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.